Drugs / ACRX-100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01082094 | Feb 2010 → Jan 2012 | heart failure | Juventas Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACRX-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01082094 ↗ |
| Route | Other | “ACRX-100 will be injected directly into the myocardium as a single dose at multiple sites through a percutaneous, left ventricular approach using a needle injection catheter.” NCT01082094 ↗ |